Skip to main content

Advertisement

Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Article metrics

The original article was published in BMC Psychiatry 2005 5:5

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].

References

  1. 1.

    Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5: 5-10.1186/1471-244X-5-5.

  2. 2.

    Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68: 29-39. 10.1016/S0024-3205(00)00911-5.

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/5/44/prepub

Download references

Author information

Correspondence to Paul D Carey.

Additional information

The online version of the original article can be found at 10.1186/1471-244X-5-5

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carey, P.D., Vythilingum, B., Seedat, S. et al. Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5, 44 (2005) doi:10.1186/1471-244X-5-44

Download citation